CHICAGO ISLET CONSORTIUM ICR AT UIC

UIC 芝加哥岛联盟 ICR

• 批准号: 7725870
• 负责人: Jose Oberholzer
• 金额: $ 109.13万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7725870
• 关键词: Accounting; American; Blindness; Blood Glucose; Cardiovascular Diseases; Chicago; Chronic; Clinical Protocols; Communities; Complex; Computer Retrieval of Information on Scientific Projects Database; Core Facility; Development; Diabetes Mellitus; Endocrine; Failure; Freedom; Funding; Glucose; Grant; Hormones; Human; Hypoglycemia; Hypoglycemic Agents; Illinois; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Kidney Failure; Laboratories; Laboratory Study; Methods; Numbers; Pancreas; Patients; Preparation; Procedures; Quality Control; Recovery of Function; Replacement Therapy; Research; Research Personnel; Resources; Shipping; Ships; Source; Techniques; Transplantation; United States National Institutes of Health; Universities; base; blood glucose regulation; cell preparation; clinical application; diabetic; improved; islet; neuronal cell body; prevent; research and development; type I diabetic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them. It is estimated that 20.8 Million Americans have diabetes; type I diabetes accounts for 5 to 10% of cases (approximately 1.56 Million type I diabetic patients). Keeping blood glucose levels under tight control represents the most effective way either to prevent the onset or to reduce the progression of the chronic complications of type I diabetes, such as blindness, kidney failure and cardiovascular diseases. Islet transplantation can achieve insulin independence, glucose control and freedom of hypoglycemic attacks in patients afflicted with Type I diabetes mellitus. However, the recovery of functional pancreatic islets from cadaveric donor pancreata is a complex procedure and needs to be optimized. Until an unlimited source of human pancreatic islet cell becomes available, the further development of endocrine replacement therapy for the treatment of diabetes will solely depend on the availability of high quality islet preparations, both for clinical application and laboratory-based research. Because of the complexity of the islet isolation procedure, it would be desirable to concentrate the know-how in a limited number of centers or consortiums to allow for optimal use of available resources. The aim of this application is to extend the existing human islet core facility at the University of Illinois and the Chicago Islet Consortium into a federally funded Islet Cell Resource Center to isolate, purify, characterize and distribute human pancreatic islet cells for both transplantation into diabetic patients and use in laboratory studies to a larger community. The ICR at UIC with its partners in the Chicago Islet Consortium will be responsible for the procurement of whole pancreata, isolation and quality control of islet cell preparations, and distribution of islets for approved research or clinical protocols. The ICR at UIC is conducting research and development to improve isolation techniques, cellular viability and function, and shipping procedures, and is investigating methods for improved assessment of islet mass, composition, quality and viability. In addition, and most importantly for the progress of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 描述（由申请人提供）：I 型糖尿病是由于身体无法产生胰岛素而导致的，胰岛素是“解锁”身体细胞的激素，允许葡萄糖进入并为细胞提供能量。据估计，有 2080 万美国人患有糖尿病； I型糖尿病占病例的5%至10%（约156万I型糖尿病患者）。严格控制血糖水平是预防 I 型糖尿病慢性并发症（如失明、肾衰竭和心血管疾病）发病或减少其进展的最有效方法。胰岛移植可以使 I 型糖尿病患者实现胰岛素独立、血糖控制和低血糖发作。然而，从尸体供体胰腺中恢复功能性胰岛是一个复杂的过程，需要优化。在获得无限的人类胰岛细胞来源之前，用于治疗糖尿病的内分泌替代疗法的进一步发展将完全取决于高质量胰岛制剂的可用性，无论是用于临床应用还是基于实验室的研究。由于胰岛分离程序的复杂性，因此希望将专业知识集中在有限数量的中心或联合体中，以实现可用资源的最佳利用。该应用的目的是将伊利诺伊大学和芝加哥胰岛联盟现有的人类胰岛核心设施扩展为联邦政府资助的胰岛细胞资源中心，以分离、纯化、表征和分配人类胰岛细胞，用于移植到糖尿病患者体内并在实验室研究中使用到更大的社区。 UIC 的 ICR 及其芝加哥胰岛联盟的合作伙伴将负责整个胰腺的采购、胰岛细胞制剂的分离和质量控制，以及为批准的研究或临床方案分配胰岛。 UIC 的 ICR 正在进行研究和开发，以改进分离技术、细胞活力和功能以及运输程序，并正在研究改进胰岛质量、成分、质量和活力评估的方法。此外，对于该领域的进步最重要的是，UIC的ICR将继续为糖尿病患者的移植提供大量高质量的胰岛制剂。